Because of their short half‐lives, currently available daily‐dosed PTH‐based therapies provide intermittent PTH exposure, stimulating osteoblastic bone formation as shown by increases in P1NP, BSAP, and trabecular BMD.21However, although anabolic activity resulting in increased BMD is the treatment goal in osteoporosis, it is not desirable in HP. The gene discussed is PTH; the disease is osteoporosis.